Athos Therapeutics is at the forefront of developing artificial intelligence-based precision therapeutics specifically aimed at treating autoimmune diseases, including Inflammatory Bowel Disease (IBD) and other inflammatory conditions. The company has established a distinctive drug discovery and development platform that integrates medicinal chemistry with systems biology, leveraging machine learning to identify and develop novel therapeutic compounds. This innovative approach begins with the identification of new factors associated with disease pathobiology by analyzing human clinical and molecular datasets. Following this, Athos synthesizes small molecules using its computational medicinal chemistry platform, which, combined with machine learning algorithms, helps pinpoint the most effective compounds that can safely target critical disease factors.

The company's pipeline includes a range of assets targeting various autoimmune diseases, such as lupus and cancer, with a focus on small molecule discovery. Athos is advancing several lead programs through different stages of development, including IBD, systemic lupus erythematosus (SLE), and other conditions like scleroderma and acute myeloid leukemia (AML). Their commitment to harnessing the power of science and artificial intelligence aims to enhance patient outcomes by delivering targeted therapies that address the underlying mechanisms of autoimmune diseases.

United States

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Athos Therapeutics

Company Details